Anakinra Clinical Trials
10 recruitingDrug
Phase 24Phase 33Phase 11Not Applicable1Phase 41
Showing 1–10 of 10 trials
Recruiting
Phase 2Phase 3
Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS
Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)
Nationwide Children's Hospital500 enrolled32 locationsNCT05267821
Recruiting
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
Lactating Women on Select DOIBreastfed Infants of Mothers on Select DOI
Duke University1,600 enrolled22 locationsNCT03511118
Recruiting
Phase 2
Interleukin-1 Blockade in Acute Myocardial Infarction to Prevent Heart Failure
Heart Failure
Virginia Commonwealth University84 enrolled2 locationsNCT05177822
Recruiting
Phase 1
The Effects of IL-1 Blockade on Inotrope Sensitivity in Patients With Heart Failure (AID-HEART)
Heart Failure
Virginia Commonwealth University20 enrolled1 locationNCT06062966
Recruiting
Phase 2
Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)
Pancreatic Adenocarcinoma
Baylor Research Institute24 enrolled1 locationNCT04926467
Recruiting
Phase 4
Immunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia
SepsisDexamethasoneNeuroinflammatory Response+4 more
Radboud University Medical Center52 enrolled1 locationNCT06624436
Recruiting
Phase 2
A Study to Evaluate Safety and Efficacy of Subcutaneous Administration of Anakinra in Patients With CF
Cystic Fibrosis, 10011762
Heidelberg University52 enrolled3 locationsNCT03925194
Recruiting
Phase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Community-acquired Pneumonia, Influenza, COVID-19
UMC Utrecht20,000 enrolled408 locationsNCT02735707
Recruiting
Not Applicable
Therapy Management in Patients Treated With Anakinra Due to Recurrent Pericarditis
Recurrent Pericarditis
Azienda Ospedaliero, Universitaria Ospedali Riuniti20 enrolled1 locationNCT06071156
Recruiting
Phase 3
Randomised Evaluation of COVID-19 Therapy
Severe Acute Respiratory Syndrome
University of Oxford70,000 enrolled7 locationsNCT04381936